Dr. Davids on the Combination of Ibrutinib and Obinutuzumab in CLL

Matthew S. Davids, MD, MMSc, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, discusses the combination of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

For patients with relapsed/refractory CLL, ibrutinib is the current standard therapy. There are many combination studies investigating ibrutinib plus obinutuzumab, explains Davids. In a phase Ib study, investigators are determining if the order of administration of ibrutinib and obinutuzumab affects the safety and the efficacy of the combination.